26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

The researchers reported that a combined oral minoxidil-finasteride regimen significantly improved hair density in men with androgenetic alopecia over 12 months, although further confirmation in different trials is suggested.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This study identified eight genetic markers associated with androgenetic alopecia, suggesting that these SNPs could influence individualized therapeutic responses and highlight the need for personalized treatment strategies.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.

This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

In this study, DHT was observed to have varying effects on hair follicle growth and related protein expression depending on concentration, with the Wnt/β-catenin pathway potentially playing a significant role.

This source reviews treatments for female pattern hair loss and discusses the challenges in achieving effective regrowth, highlighting the need for combinations of topical, systemic, and interventional therapies.

This study suggests that minoxidil may enhance hair growth by stimulating adipose-derived stem cell motility and growth factor secretion, promoting dermal papilla cell proliferation and accelerating anagen induction.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.

This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

The 5% minoxidil solution effectively treated hair loss with good tolerability.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This article discusses the use of topical estrogen therapy for androgenetic alopecia in menopausal females and reports no new clinical results.

This study found no significant associations between the polymorphisms of SRD5A1 and SRD5A2 genes and androgenetic alopecia, clinical types of baldness, or response to finasteride in Koreans.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

This study suggests that minoxidil activates PGHS-1, which may explain its hair growth-stimulating effects and could aid in designing more potent hair growth-promoting drugs.